Fc Fusion Protein Market to Reach $88.6 Billion by 2036 as Biosimilars Lift 8.3% CAGR
Updated
Updated · futuremarketinsights.com · Aug 10
Fc Fusion Protein Market to Reach $88.6 Billion by 2036 as Biosimilars Lift 8.3% CAGR
1 articles · Updated · futuremarketinsights.com · Aug 10
Summary
$39.9 billion in 2026 Fc fusion protein sales are projected to more than double to $88.6 billion by 2036, adding about $48.9 billion in value.
8.3% annual growth is tied to repeat demand in chronic inflammatory, bleeding and retinal disorders, where established biologics and newer biosimilars are widening treatment access.
67% of 2026 product demand is expected to come from therapeutic Fc fusion proteins, while autoimmune diseases account for 46% of applications and injectables dominate 91% of route demand.
Aflibercept biosimilars are a key growth lever after the FDA's 2025 approval of Celltrion's EYDENZELT, though payer reimbursement, clinic injection capacity and sterile supply still shape adoption.
Japan leads the profiled country outlook at 8.1% CAGR, ahead of the U.S. at 8.0%, with all five named markets growing slightly below the global forecast.
Could hidden manufacturing bottlenecks and strict regulatory hurdles derail the projected $88.6 billion boom in the Fc fusion protein market?
How might AI-guided protein design disrupt traditional mammalian cell manufacturing for complex Fc fusion biologics before 2036?
With aflibercept biosimilars flooding the market, will off-label handling risks compromise patient safety in the race for affordable retinal treatments?